Ideaya announces FDA nod to run Amgen-sponsored tumor study
Grandbrothers

Ideaya Biosciences (NASDAQ:IDYA) announced Monday that the FDA greenlighted an Investigational New Drug (IND) application paving the way for a trial sponsored by Amgen (NASDAQ:AMGN) to study a tumor candidate.
The Phase 1/2 trial is designed to evaluate one of Ideayaâs (IDYA) lead product candidates called IDE397 with AMG 193 in solid tumors with MTAP deletion.

At the 2023 Annual Meeting of the American Association for Cancer Research, Ideaya (IDYA) and Amgen (AMGN) shared preclinical data to highlight the anti-tumor effects of IDE397 in combination with AMG 193.

Citing preclinical data for the drug combo, the medical chief of IDYA, Dr. Darrin Beaupre, noted: âWe believe that evaluation of this combination represents an exciting and highly rational clinical study for patients with MTAP-deletion tumors.â


More on Ideaya

Ideaya, Pfizer amend clinical trials supply contacts for darovasertib, Xalkori for eye cancer
Ideaya Biosciences Has A Strong Pipeline And Looks Investible